BACKGROUND The negative symptoms of schizophrenia are not effectively treated with antipsychotic medications. Repetitive transcranial magnetic stimulation (rTMS) is an alternative approach that may be more effective in treating negative symptoms, but there has been little research comparing the effectiveness of different rTMS stimulation protocols. OBJECTIVE Compare the effect of four differe...

OBJECTIVE This pilot, twelve-week, open-label study examined the effect of clozapine orally disintegrating tablet or ODT in patients with schizophrenia and schizoaffective disorder utilizing Positive and Negative Syndrome Scale (PANSS) as a long-term outcome measurement tool. METHODS The final study sample consisted of nineteen subjects who were residents a long-term care psychiatric facility...

Although several studies have pointed to a possible role of interleukin 2 (IL-2) in schizophrenia (SZ), association between IL-2 and the different groups of symptoms has not been explored. The objective of this study was to investigate a possible correlation of peripheral IL-2 levels with symptoms and cognitive performance in patients with SZ. In addition, we compared the plasma levels of IL-2 ...

recently, extensive efforts have been made to understand the rate of energy expenditure and the weight gain associated with atypical antipsychotic treatment, including identification of markers of obesity risk. in recent years, leptin, an adipocyte hormone, has gained significant interest in psychiatric disorders. s100b has been considered as a surrogate marker for astrocyte-specific damage in ...

Abstract Introduction KarXT combines the M 1 /M 4 preferring muscarinic receptor agonist xanomeline and peripherally restricted anticholinergic trospium. In phase 2 EMERGENT-1 study, met primary endpoint of a significant reduction in Positive Negative Syndrome Scale (PANSS) total score through week 5 vs placebo, improved other key secondary efficacy measures, was generally well tolerated. Metho...

BACKGROUND Early improvement with treatment is thought to be important in patients with first-episode schizophrenia, yet a valid definition is still outstanding. AIMS To develop a valid definition of early improvement and test its predictive validity regarding response and remission. METHOD We examined 188 in-patients with first-episode schizophrenia. Early improvement was defined as improv...

OBJECTIVE This study was designed to evaluate the short-term efficacy and safety of once-daily lurasidone (80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of schizophrenia. METHODS Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly assigned to 6 weeks of fixed-dose, double-blind treatment w...

Abstract Inadequate response to antipsychotic treatment is common in patients with schizophrenia. This study evaluated pimavanserin, a 5-HT2A receptor inverse agonist/antagonist, as adjunctive inadequate response. was 6-week, randomized, double-blind, placebo-controlled, conducted North America and Europe. Adult outpatients schizophrenia current were enrolled. Inclusion criteria included Positi...

The Clinical Assessment Interview for Negative Symptoms (CAINS) was developed to overcome the limitations of existing instruments and reflect the current view of negative symptoms. The aim of the present study was to evaluate the reliability and validity of the Korean version of the Clinical Assessment Interview for Negative Symptoms (K-CAINS). Inpatients (n = 49) and outpatients (n = 70) with ...

OBJECTIVE Lack of insight into illness has long been recognized as a central characteristic of schizophrenia. Although recent theories have emphasized neurocognitive dysfunction as a central impairment in schizophrenia it remains unclear whether the lack of insight in schizophrenia is more strongly associated with measures of symptom severity or neuropsychological dysfunction. METHODS Seventy...